Correcting Hypophosphatemia with Sodium Glycerophosphate

Introduction to Sodium Glycerophosphate

• Sodium glycerophosphate serves as both a calcium and phosphorus source when used in parenteral nutrition solutions, with the key advantage of avoiding precipitation with calcium in intravenous solutions 1

Dosing Strategy for Hypophosphatemia Correction

• For moderate to severe hypophosphatemia, initiate phosphate supplementation at 20-60 mg/kg/day of elemental phosphorus divided into 4-6 doses, with a maximum dose not exceeding 80 mg/kg/day to prevent gastrointestinal discomfort and secondary hyperparathyroidism 2, 4
• Severe hypophosphatemia is defined as serum phosphorus <1.5 mg/dL 3

Mandatory Adjunctive Vitamin D Therapy

• Active vitamin D must be given concurrently with phosphate supplementation to counter calcitriol deficiency, prevent secondary hyperparathyroidism, and increase intestinal phosphate absorption, with calcitriol dosing at 20-30 ng/kg/day in children or 0.50-0.75 μg daily in adults, and alfacalcidol dosing at 30-50 ng/kg/day in children or 0.75-1.5 μg daily in adults 2, 3, 4

Monitoring Protocol

• Check serum phosphorus, calcium, potassium, and magnesium every 1-2 days until stable, targeting phosphorus levels at the lower end of normal range (2.5-3.0 mg/dL) rather than complete normalization 2, 3
• Monitor alkaline phosphatase and PTH levels every 3-6 months to assess treatment adequacy, and check renal function (eGFR) and urinary calcium to detect complications 2, 3

Critical Administration Guidelines

• Phosphate supplements should never be administered with calcium-containing foods or supplements, as precipitation in the intestinal tract reduces absorption 3, 4
• Give active vitamin D in the evening to reduce calcium absorption after meals and minimize hypercalciuria 3

Special Populations and Precautions

• Use lower doses and monitor more frequently in patients with reduced kidney function, avoiding IV phosphate in severe renal impairment (eGFR <30-60 mL/min/1.73m²) due to risk of hyperphosphatemia 2
• Decrease or stop active vitamin D if patients are immobilized for prolonged periods (>1 week) to prevent hypercalciuria and nephrocalcinosis risk, restarting therapy when ambulating 4